Pure Global AI
NCT06151249Not yet recruiting

Evaluate the Meritup Oral Solution to Decrease Fatigue in Metastatic Breast Cancer Patients Receiving Chemotherapy

A Randomized, Double-blind, Placebo-controlled, Parallel Study to Evaluate the Safety and Ability of Meritup Oral Liquid to Reduce Fatigue in Patients With Metastatic Breast Cancer Receiving Chemotherapy
Chung Shan Medical UniversityPhase 2ClinicalTrials.govcombination product
Verified
Study focus
Disease/Condition
Metastatic Breast Cancer
Drug/Device/Intervention
Meritup oral solution
Study type
Interventional
Intervention type
combination product
Sponsor & location
Primary sponsor
Chung Shan Medical University
Timeline & enrollment
Phase
Phase 2
Start date
Dec 01, 2023
End date
Nov 30, 2025
Enrollment
32 participants
Primary outcome

Changes in fatigue scores

Summary

A randomized, double-blind, placebo-controlled, parallel study to evaluate the safety profile
 and ability of Meritup oral solution to decrease fatigue in metastatic breast cancer patients
 receiving chemotherapy.

ICD-10 classifications
Malignant neoplasm of breastMalignant neoplasm of breastMalignant neoplasm: Breast, unspecifiedMalignant neoplasm: Central portion of breastMalignant neoplasm: Overlapping lesion of breast
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06151249
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06151249 through Pure Global AI's free database. This Phase 2 trial is sponsored by Chung Shan Medical University and is currently Not yet recruiting. The study focuses on Metastatic Breast Cancer. Target enrollment is 32 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.